Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein

发现和开发针对 UL89 终止酶蛋白的新型抗 HCMV 药物

基本信息

  • 批准号:
    10534193
  • 负责人:
  • 金额:
    $ 65.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-25 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Human cytomegalovirus (HCMV) infection in individuals lacking a fully functioning immune system, such as newborns and transplant patients, can result in severe and debilitating consequences. The majority of the US Food and Drug Administration approved anti-HCMV drugs target the viral polymerase and resistance to those drugs has appeared. Therefore, anti-HCMV drugs from novel targets are needed for use in combination with, or instead of, current polymerase inhibitors. The long-term goal of this proposal is to develop structurally novel direct-acting antivirals against HCMV targeting aspects of virus replication outside of those for currently approved drugs. Towards this end, a viral ATPase/endonuclease (pUL89) critically involved in viral genome packaging and virus assembly has been chosen as a target for antiviral intervention. The objective of this investigation is to identify, optimize and characterize pUL89 inhibitor scaffolds. To accomplish these goals, the following specific aims will be pursued: 1. Develop and implement screening assays to identify pUL89 and HCMV inhibitors. These assays include biochemical assays for pUL89 function as well as HCMV replication assays in cell culture. 2. HCMV pUL89 inhibitor hit generation and optimization. Hit generation will center around the focused screening of in-house synthetic small molecules and select compound libraries. Confirmed hits will be optimized via analogue synthesis, iterative SAR and in vitro ADME assays to generate potent inhibitors with favorable physicochemical properties. 3. Characterization of advanced inhibitors using virological, structural and pharmacokinetic techniques. Optimized inhibitor binding to pUL89 will be analyzed and refined using structural studies. Detailed virological experiments will be performed to characterize the mechanism of action, verify the target of these inhibitors and document their ability to work with current FDA approved drugs and against resistant virus. In addition, in vivo pharmacokinetic parameters of the optimized inhibitors will be determined and used to improve drug-like properties. At the conclusion of the studies outlined in this proposal, a better understanding of the mechanism of action and role of pUL89 endonuclease activity in virus replication will be gained and multiple potent preclinical drug candidates targeting pUL89 will be developed.
项目总结/文摘

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Repurposing N-hydroxy thienopyrimidine-2,4-diones (HtPD) as inhibitors of human cytomegalovirus pUL89 endonuclease: Synthesis and biological characterization.
  • DOI:
    10.1016/j.bioorg.2022.106198
  • 发表时间:
    2022-12
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
    He T;Edwards TC;Majima R;Jung E;Kankanala J;Xie J;Geraghty RJ;Wang Z
  • 通讯作者:
    Wang Z
Discovery of N-benzyl hydroxypyridone carboxamides as a novel and potent antiviral chemotype against human cytomegalovirus (HCMV).
  • DOI:
    10.1016/j.apsb.2021.08.019
  • 发表时间:
    2022-04
  • 期刊:
  • 影响因子:
    14.5
  • 作者:
    Senaweera, Sameera;Edwards, Tiffany C.;Kankanala, Jayakanth;Wang, Yan;Sahani, Rajkumar Lalji;Xie, Jiashu;Geraghty, Robert J.;Wang, Zhengqiang
  • 通讯作者:
    Wang, Zhengqiang
8-Hydroxy-1,6-naphthyridine-7-carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.
8-羟基-1,6-萘吡啶-7-羧酰胺作为人类巨细胞病毒PUL89核酸内切酶的抑制剂。
  • DOI:
    10.1002/cmdc.202200334
  • 发表时间:
    2022-09-05
  • 期刊:
  • 影响因子:
    3.4
  • 作者:
    Jung, Eunkyung;Majima, Ryuichi;Edwards, Tiffany C.;Soto-Acosta, Ruben;Geraghty, Robert J.;Wang, Zhengqiang
  • 通讯作者:
    Wang, Zhengqiang
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert James Geraghty其他文献

Robert James Geraghty的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert James Geraghty', 18)}}的其他基金

Discovery and development of novel anti-HCMV agents targeting the UL89 terminase protein
发现和开发针对 UL89 终止酶蛋白的新型抗 HCMV 药物
  • 批准号:
    10318943
  • 财政年份:
    2019
  • 资助金额:
    $ 65.45万
  • 项目类别:
Membrane fusion during HSV-1 entry
HSV-1 进入期间的膜融合
  • 批准号:
    7447258
  • 财政年份:
    2009
  • 资助金额:
    $ 65.45万
  • 项目类别:
Membrane fusion during HSV-1 entry
HSV-1 进入期间的膜融合
  • 批准号:
    7843510
  • 财政年份:
    2009
  • 资助金额:
    $ 65.45万
  • 项目类别:
Spread of HSV-1 mediated by the gD receptor nectin-1
gD 受体 nectin-1 介导的 HSV-1 传播
  • 批准号:
    6667357
  • 财政年份:
    2002
  • 资助金额:
    $ 65.45万
  • 项目类别:
Spread of HSV-1 mediated by the gD receptor nectin-1
gD 受体 nectin-1 介导的 HSV-1 传播
  • 批准号:
    6706949
  • 财政年份:
    2002
  • 资助金额:
    $ 65.45万
  • 项目类别:
Spread of HSV-1 mediated by the gD receptor nectin-1
gD 受体 nectin-1 介导的 HSV-1 传播
  • 批准号:
    6860144
  • 财政年份:
    2002
  • 资助金额:
    $ 65.45万
  • 项目类别:
Spread of HSV-1 mediated by the gD receptor nectin-1
gD 受体 nectin-1 介导的 HSV-1 传播
  • 批准号:
    7031532
  • 财政年份:
    2002
  • 资助金额:
    $ 65.45万
  • 项目类别:
Spread of HSV-1 mediated by the gD receptor nectin-1
gD 受体 nectin-1 介导的 HSV-1 传播
  • 批准号:
    6461587
  • 财政年份:
    2002
  • 资助金额:
    $ 65.45万
  • 项目类别:
PROTEIN INTERACTIONS IN HERPESVIRUS CELL FUSION
疱疹病毒细胞融合中的蛋白质相互作用
  • 批准号:
    2671615
  • 财政年份:
    1998
  • 资助金额:
    $ 65.45万
  • 项目类别:
PROTEIN INTERACTIONS IN HERPESVIRUS CELL FUSION
疱疹病毒细胞融合中的蛋白质相互作用
  • 批准号:
    2643308
  • 财政年份:
    1997
  • 资助金额:
    $ 65.45万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 65.45万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 65.45万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 65.45万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 65.45万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 65.45万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 65.45万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 65.45万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 65.45万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 65.45万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 65.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了